Max Rosett
Finanzdirektor/CFO bei IMMUNOME, INC.
Vermögen: 283 147 $ am 30.04.2024
Profil
Max Rosett is currently working as the CFO, Chief Accounting Officer & EVP-Operations at Immunome, Inc. He previously worked as the Chief Operating Officer at MorphImmune, Inc. from 2022 to 2023 and as a Principal at Research Bridge Partners from 2018 to 2023.
Mr. Rosett graduated from the Georgia Institute of Technology in 2016 with a graduate degree and from Yale University in 2012 with an undergraduate degree.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IMMUNOME, INC.
0,03% | 31.01.2024 | 19 856 ( 0,03% ) | 283 147 $ | 30.04.2024 |
Aktive Positionen von Max Rosett
| Unternehmen | Position | Beginn |
|---|---|---|
| IMMUNOME, INC. | Finanzdirektor/CFO | 02.01.2024 |
Ehemalige bekannte Positionen von Max Rosett
| Unternehmen | Position | Ende |
|---|---|---|
Research Bridge Partners /Venture Capital/
 Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas. | Corporate Officer/Principal | 01.11.2023 |
MorphImmune, Inc.
 MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Geschäftsführer | 01.10.2023 |
Ausbildung von Max Rosett
| Yale University | Undergraduate Degree |
| Georgia Institute of Technology | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| IMMUNOME, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Health Technology |
Research Bridge Partners /Venture Capital/
Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas. | Finance |
